Resultados: 22

    Guideline No. 420: cytomegalovirus Infection in Pregnancy

    J. obstet. gynaecol. Can; 43 (7), 2021
    To provide an update on current recommendations for cytomegalovirus (CMV) infection during pregnancy. The objectives of this guideline are: To improve perinatal care providers’ awareness of the consequences of maternal CMV infection for the fetus and the infant; To emphasize the importance of educating...

    Guideline No. 410: prevention, screening, diagnosis, and pregnancy Management for fetal neural tube defects

    J. obstet. gynaecol. Can; 43 (1), 2021
    This revised guideline is intended to provide an update on the genetic aspects, prevention, screening, diagnosis, and management of fetal neural tube defects. Target population: Women who are pregnant or may become pregnant. Neural tube defect screening should be offered to all pregnant women. For preven...

    Guideline No. 408: management of gestational trophoblastic diseases

    J. obstet. gynaecol. Can; 43 (1), 2021
    This guideline reviews the clinical evaluation and management of gestational trophoblastic diseases, including surgical and medical management of benign, premalignant, and malignant entities. The objective of this guideline is to assist health care providers in promptly diagnosing gestational trophoblast...

    Guideline No. 409: intrauterine fetal diagnostic testing in women with chronic viral infections

    J. obstet. gynaecol. Can; 42 (12), 2020
    This revised guideline provides updated information for the care of women with chronic viral infections who require intrauterine fetal diagnostic testing. Women with chronic viral infections who are pregnant or planning a pregnancy. Non-invasive screening tests for diagnosis: maternal serum placental ana...

    Guideline No. 401: sonographic cervical length in Singleton Pregnancies: techniques and clinical applications

    J. obstet. gynaecol. Can; 42 (11), 2020
    To assess the association between sonography-derived cervical length measurement and preterm birth. To describe the various techniques to measure cervical length using sonography. To review the natural history of the short cervix. To review the clinical uses, predictive ability, and utility of sonography...

    Guideline No. 405: screening and counselling for alcohol consumption during pregnancy

    J. obstet. gynaecol. Can; 42 (9), 2020
    To establish national standards of care for screening and counselling pregnant women and women of child-bearing age about alcohol consumption and possible alcohol use disorder based on current best evidence. Health care providers who care for pregnant women and women of child-bearing age. Pregnant women ...

    Guideline No. 403: initial investigation and management of adnexal masses

    J. obstet. gynaecol. Can; 42 (8), 2020
    To aid primary care physicians, emergency medicine physicians, and gynaecologists in the initial investigation of adnexal masses, defined as lumps that appear near the uterus or in or around ovaries, fallopian tubes, or surrounding connective tissue, and to outline recommendations for identifying women w...

    Guideline No. 404: initial investigation and management of benign ovarian masses

    J. obstet. gynaecol. Can; 42 (8), 2020
    To provide recommendations for a systematic approach to the initial investigation and management of a benign ovarian mass and facilitate patient referral to a gynaecologic oncologist for management....

    Guideline No. 402: diagnosis and management of placenta previa

    J. obstet. gynaecol. Can; 42 (7), 2020
    To summarize the current evidence and to make recommendations for diagnosis and classification of placenta previa and for managing the care of women with this diagnosis. To manage in hospital or as an outpatient and to perform a cesarean delivery preterm or at term or to allow a trial of labour when a di...

    Guideline No. 398: progesterone for prevention of spontaneous preterm birth

    J. obstet. gynaecol. Can; 42 (6), 2020
    To assess the benefits and risks of progesterone therapy for women at increased risk of spontaneous preterm birth (SPB) and to make recommendations for the use of progesterone to reduce the risk of SPB and improve postnatal outcomes. To administer or withhold progesterone therapy for women deemed to be a...